Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

509 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy.
Díaz-Santa J, Rodríguez-Romanos R, Osca G, Pratcorona M, Garrido A, Coll R, Moret C, Escoda L, Tormo M, Heras I, Arnan M, Vives S, Salamero O, Lloveras N, Bargay J, Sampol A, Cruz D, Garcia A, Quiñones T, Esteve J, Sierra J, Gallardo D; on the behalf of CETLAM Group. Díaz-Santa J, et al. Among authors: garrido a. Leukemia. 2020 Nov;34(11):2925-2933. doi: 10.1038/s41375-020-0784-2. Epub 2020 Mar 9. Leukemia. 2020. PMID: 32152464
Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease.
García-Cadenas I, Valcárcel D, Martino R, Piñana JL, Novelli S, Esquirol A, Garrido A, Moreno ME, Granell M, Moreno C, Saavedra S, Briones J, Brunet S, Sierra J. García-Cadenas I, et al. Among authors: garrido a. Biol Blood Marrow Transplant. 2013 Mar;19(3):435-9. doi: 10.1016/j.bbmt.2012.11.012. Epub 2012 Nov 20. Biol Blood Marrow Transplant. 2013. PMID: 23178634 Free article.
Impact of cyclosporine levels on the development of acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation.
García Cadenas I, Valcarcel D, Martino R, Piñana JL, Barba P, Novelli S, Esquirol A, Garrido A, Saavedra S, Granell M, Moreno C, Briones J, Brunet S, Sierra J. García Cadenas I, et al. Among authors: garrido a. Mediators Inflamm. 2014;2014:620682. doi: 10.1155/2014/620682. Epub 2014 Jan 30. Mediators Inflamm. 2014. PMID: 24623962 Free PMC article.
Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.
Rozman M, Navarro JT, Arenillas L, Aventín A, Giménez T, Alonso E, Perea G, Camós M, Navarrete M, Tuset E, Florensa L, Millá F, Nomdedéu J, de la Banda E, Díaz-Beyá M, Pratcorona M, Garrido A, Navarro B, Brunet S, Sierra J, Esteve J; Grup Català de Citologia Hematològica and Spanish CETLAM Group (Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas). Rozman M, et al. Among authors: garrido a. Ann Hematol. 2014 Oct;93(10):1695-703. doi: 10.1007/s00277-014-2100-6. Epub 2014 May 14. Ann Hematol. 2014. PMID: 24824767
FcγRIIb expression in early stage chronic lymphocytic leukemia.
Bosch R, Mora A, Vicente EP, Ferrer G, Jansà S, Damle R, Gorlatov S, Rai K, Montserrat E, Nomdedeu J, Pratcorona M, Blanco L, Saavedra S, Garrido A, Esquirol A, Garcia I, Granell M, Martino R, Delgado J, Sierra J, Chiorazzi N, Moreno C. Bosch R, et al. Among authors: garrido a. Leuk Lymphoma. 2017 Nov;58(11):2642-2648. doi: 10.1080/10428194.2017.1307981. Epub 2017 Apr 4. Leuk Lymphoma. 2017. PMID: 28372509 Free PMC article.
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.
Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, Pinto R, Maurillo L, Wetzel J, Musto P, Van De Loosdrecht AA, Costa MJ, Esteves S, Burgstaller S, Stauder R, Autzinger EM, Lang A, Krippl P, Geissler D, Falantes JF, Pedro C, Bargay J, Deben G, Garrido A, Bonanad S, Diez-Campelo M, Thepot S, Ades L, Sperr WR, Valent P, Fenaux P, Sekeres MA, Greil R, Pleyer L. Almeida AM, et al. Among authors: garrido a. Int J Mol Sci. 2017 Apr 14;18(4):837. doi: 10.3390/ijms18040837. Int J Mol Sci. 2017. PMID: 28420120 Free PMC article.
Bone Marrow WT1 Levels in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplasia: Clinically Relevant Time Points and 100 Copies Threshold Value.
Nomdedéu JF, Esquirol A, Carricondo M, Pratcorona M, Hoyos M, Garrido A, Rubio M, Bussaglia E, García-Cadenas I, Estivill C, Brunet S, Martino R, Sierra J. Nomdedéu JF, et al. Among authors: garrido a. Biol Blood Marrow Transplant. 2018 Jan;24(1):55-63. doi: 10.1016/j.bbmt.2017.09.001. Epub 2017 Sep 20. Biol Blood Marrow Transplant. 2018. PMID: 28939453 Free article.
Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival.
Guillem V, Calabuig M, Brunet S, Esteve J, Escoda L, Gallardo D, Ribera JM, Queipo de Llano MP, Arnan M, Pedro C, Amigo ML, Martí-Tutusaus JM, García-Guiñón A, Bargay J, Sampol A, Salamero O, Font L, Talarn C, Hoyos M, Díaz-Beyá M, Garrido A, Navarro B, Nomdédeu J, Sierra J, Tormo M. Guillem V, et al. Among authors: garrido a. Leuk Lymphoma. 2018 Oct;59(10):2383-2393. doi: 10.1080/10428194.2017.1422858. Epub 2018 Jan 18. Leuk Lymphoma. 2018. PMID: 29345176
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P; CETLAM and PETHEMA groups. Martínez-Cuadrón D, et al. Among authors: garrido a. Ann Hematol. 2018 May;97(5):763-772. doi: 10.1007/s00277-018-3229-5. Epub 2018 Feb 2. Ann Hematol. 2018. PMID: 29392425 Clinical Trial.
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P; CETLAM and PETHEMA groups. Martínez-Cuadrón D, et al. Among authors: garrido a. Ann Hematol. 2018 May;97(5):923. doi: 10.1007/s00277-018-3277-x. Ann Hematol. 2018. PMID: 29473097 Free article.
509 results